X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

The Fauna Pharmaceutical Pollution: Scientists Sound Alarm

Content Team by Content Team
27th June 2024
in News
The Fauna Pharmaceutical Pollution: Scientists Sound Alarm

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

There is not a shred of doubt when we say that the ecosystem of the planet is getting contaminated due to Active Pharmaceutical Ingredients- APIs which are indeed a rising danger when it comes to wildlife and human health, of course.

There are efforts that are put-in to upgrading wastewater treatment infrastructure so as to eliminate drugs before they get released into waterways. However, the fact is that greener drugs need to be designed so as to lessen the environmental impact, as per 17 leading international scientists who went on to publish a new study in Nature Sustainability.

Greener drugs go on to reduce the potential for pollution all across the life cycle. The fact is that humans happen to be living in a very medicated world, with pharmaceutical drugs being an integral part of it today and in the future too. However, the dependence on pharma has indeed come at a massive cost.

Discharges to the ecology during the course of drug production have seen the ecosystem get contaminated with a mix of APIs and their additives, metabolites, excipients, adjuvants, and transformation products.

Apparently, there is a wide spectrum of drugs that are detected across the environments throughout all the continents of the earth. Exposure to a trace concentration of the drugs can go on to have a very severe impact on human health as well as that of wildlife.

The pharmaceutical pollutants go on to represent a specific, intricate challenge due to the fact that there are various kinds of drugs that have been detected within the ecosystem across the world. These drugs have a wide range of effects. The fact is that the drugs have to be designed to not only be safe and effective, but they should also have a lower potential risk to human and wildlife health when they are present in the environment.

The pollutants in the Environment

It is the same trait of pharma that makes them effective in animals and humans that also makes them potentially hazardous to the environment. Drugs happen to be specifically designed so as to have biological effects, and that too at low doses.

It is well to be noted that the extent of API pollution was seen in a large-scale study that happened to measure 60 varied drugs in river water and was taken from 1052 locations in 104 nations.

Around 43% of the sampled elements had levels of on drug at least that went on to exceed what is considered to be safe for ecological health.

Wildlife Threat

There is evidence that has grown in number that says that exposure when it comes to the trace concentrations of APIs as well as their mix can go on to cause critical developmental, physiological, behavioural, and morphological alterations across wildlife.

The point here is that API pollution poses a threat to humans and fauna alike, as witnessed in the antibiotic release scenario within the environment, which can indeed act as a selection pressure that promotes the mobilization and also the horizontal transfer of a range of genes pertaining to antibiotic resistance.

The drug cycle and the need for reformation

So as to decrease the pollution of drugs, the pharmaceutical sector as well as its customers have to assess as well as reform numerous elements of the intricate drug life cycle. One needs to be more informed about sustainable prescribing practices and usage since most environmentally sustainable pharmaceuticals are not needed and, as a matter of fact, not prescribed.

There is going to be a need for the training of pharmacists, nurses, physicians as well as veterinarians and there have to be guidelines issues that have in them the environmental effect of medicines.

To start with, public awareness campaigns will be pretty important given that there is at present limited know-how on prescribed and also OTC medications, which can have a drastic effect on the ecology by way of, if not an apt disposal. The main element to reforming the drug life cycle happens to be the design in terms of greener pharmaceuticals, which happen to be more easily as well as completely degraded within the ecology.

It is well to be noted that robust regulations along with rising oversight are also required, like the polluter pays principle, where the one who happens to be polluting should go on to bear the cost of control along with the prevention measures.

As per a figure, at least 48% of the overall wastewater across the world flows through into the ecosystem sans any kind of a treatment thereby highlighting the urgent requirement to raise the geographical extent of infrastructure related to wastewater treatment. It is worth noting that it is only Switzerland that has gone on to execute advanced tertiary treatment of wastewater at a national level.

There are, however, barriers that do exist on the path to greener and more sustainable drug design, such as rising economic and time investment within research, development, as well as manufacturing processes.

There are several pharmaceuticals that are already on the market that haven’t been designed intentionally taking into mind environmental sustainability, however, they are readily biodegradable in the environment.

Greener Drugs

Due to the fact that drug design happens to be the first step in the pharmaceutical life cycle, greener drugs go on to decrease the potential when it comes to pollution across the lifecycle.

The contamination of the ecosystem due to pharmaceuticals happens to be exacerbated by way of other widespread environmental transitions such as habitat destruction, climate change, etc. The point is that the drugs in the environment have been a rising issue for quite some time now. However, with evidence pertaining to adverse effects on wildlife, along with a lack of data in relation to the environmental risks of most of the drugs, and a marked rise in the use of many types of drugs, one needs to better make sure that human medicines go on to pose as minimal a threat to the wildlife as there can possibly be.

Previous Post

4% CAGR Till 2030 For Water & Wastewater Treatment Equipment

Next Post

Water Unit of DuPont Has Some Potential Buyers Interested

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Water Unit of DuPont Has Some Potential Buyers Interested

Water Unit of DuPont Has Some Potential Buyers Interested

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In